The AI Healthcare Podcast Dylan Reid

How do we expedite the drug approval process in the United States? Co-Founder & CEO of EVQLV, Andrew Satz, educates us on how and what is needed to do so. 

To find out more about Andrew, please find him on LinkedIn here: https://www.linkedin.com/in/andrewsatz/

To find out more about EVQLV, please find the company website here: https://evqlv.com/

Key takeaways:

1. The acceleration of getting drugs to patients by decreasing costs for researchers, industry, and other key stakeholders motivates EVQLV.

2. A.I. will cause hyper-specialization, which will make doctors become more productive. 

3. Making data more accessible through government agencies and investing at a governmental level will drive future A.I.  models and specialized medicines for populations.

What is brain health? CEO + Co-Founder of DigiCARE Realized and Global Consortium Member of Social Impact Partners educates us on why brain health is crucial in pushing healthcare forward in the United States.

To connect with Brittany please find her Linkedin here. 

Key takeaways:

1.Being intentional for treatments and cures are needed to make the necessary advancements for brain health so that families or those impacted have access to the resources that they need. 

2. Having an understanding of the pathology of diseases, such as Alzheimer's can provide clinicians with more personalized, effective treatment plans.

3.Shifting from being reactive to proactive is essential to understanding brain health.

Have you ever been curious about learning about navigating the U.S. Healthcare System from the perspective of an immigrant? In this interview, I sit down with my friend and COO of BeKey, Alex Koshykov on his story on navigating healthcare in the United States and its differences to his home country of Ukraine.

Connect with Alex here. 

Be sure to read his newsletter US Healthcare, which can be found on his Linkedin!

What does the future of A.I. in healthcare look like in Australia? Where are the potential challenges and opportunities for implementing A.I. technology in the country? Come learn from Australia A.I. Healthcare expert and Founder of NurseFusion, Sarah Hughes, as we uncover these questions. We had to switch to Zoom because of some technical difficulties. 

Linkedin:   / sarahhughesleadingchange 

Nursefusion Website: https://nursefusion.com.au/

Cover/Episode Art made by Daniel Maley with Dall-E

Where are EU regulations headed when it comes to A.I. in healthcare? With his expertise in the Italian market in pharmaceutical marketing and sales, Manuel Mitola, MBA Mitola teaches us how A.I. is being adopted and used in Europe. He also educates us on key legislative priorities while also balancing innovation on the European continent.

Key takeaways:

1. Each Italian state has slightly different rules in the marketing of pharmaceuticals depending on the region.

2. GDPR does not explicitly mention A.I. because the regulation came into being before A.I. was broadly known and the law is vague on prescriptions.

3. Pharmaceutical companies in Europe are risk adverse in Europe and interpret GRPR in the most conservative manner, which means applying a limitation on the usage of data.

The A.I. Healthcare Podcast is now part of the Forest Hill Labs Family.

Sign up at www.foresthilllabs.net to get Forest Hill Labs: A Health Market Intelligence, Policy, and Thought Leadership Consultancy content!